Sage Chemical, Inc. et al v. Supernus Pharmaceuticals, Inc. et al

  1. March 25, 2026

    Insurer Need Not Cover Parkinson's Drug Antitrust Dispute

    An insurer does not owe coverage in an antitrust suit accusing a pharmaceutical company of suppressing generic versions of the Parkinson's treatment Apokyn, a Maryland federal judge ruled, finding the dispute does not involve "securities claims" covered under the insurer's policy.

  2. May 10, 2024

    Pharmaceutical Cos. Can't Nix Parkinson's Drug Antitrust Suit

    A Delaware federal judge has issued a sealed order refusing to dismiss drugmakers Sage Chemical Inc. and TruPharma's antitrust suit accusing rival Supernus Pharmaceuticals and others of suppressing generic versions of the Parkinson's treatment Apokyn.

  3. March 21, 2023

    FTC Warns Of Harm In Generic Parkinson's Drug Antitrust Suit

    The Federal Trade Commission told a Delaware federal court that patients could be significantly harmed by the types of distribution restrictions and other activity that Sage Chemical Inc. accuses its rivals of using to block generic competition for Parkinson's drug Apokyn.

  4. December 21, 2022

    Drugmaker Dinged For Flouting Del. Court's Counsel Rule

    Delaware's chief federal judge has ordered drugmaker Sage Chemical to retain new counsel if it wants to continue pursuing its antitrust suit against rival Supernus and others over Parkinson's drug Apokyn, finding that Sage's representation disregarded a court rule requiring an association with "Delaware counsel."